Intelligence / Semaglutide

Semaglutide

Prescription Only
GLP-1 Agonist
Schedule
S4
Prescription Only
Enforcement
Tightening
Low Risk
Providers
12
Access: Clear
Key Facts
Schedule 4 - Prescription Only
GLP-1 receptor agonist
TGA-approved branded products available
Compounded versions under increased scrutiny
Import restrictions tightened February 2026

Overview

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes management. It is available in Australia as branded products (Ozempic, Wegovy) and through compounding pharmacies. The TGA has increased regulatory scrutiny on compounded versions following supply shortages.

Australian Scheduling

Schedule 4 (Prescription Only). TGA-approved branded products are listed on the ARTG. Compounded semaglutide is available under pharmacy compounding exemptions. Import restrictions were tightened in February 2026.

Access Pathway

Available through telehealth clinics and compounding pharmacies. Branded versions (Ozempic, Wegovy) can be prescribed by any GP. Compounded versions are available through specialised providers but face increasing regulatory scrutiny.

Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

News & Updates20 items
Counterfeit weight loss products claiming to contain GLP-1
TGA2 Mar 2026
Compounding safety information: semaglutide-like products
TGA12 Feb 2026
WHO issues global guideline on the use of GLP-1 medicines in treating obesity
WHO1 Dec 2025
Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists
TGA5 Nov 2025
Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP)
The Lancet1 Jan 2025
Wegovy recommended for PBS listing
RACGP1 Jan 2025
Update: Ozempic supply to remain limited in 2025
TGA1 Jan 2025
Semaglutide for cardiovascular risk reduction in people with obesity (new indication)
Australian Prescriber1 Dec 2024
AusPAR: Wegovy (semaglutide) TGA Approval
TGA4 Sept 2024
Effects of Semaglutide on Chronic Kidney Disease (FLOW Trial)
NEJM24 May 2024
Butler slaps ban on compounded semaglutide and tirzepatide
Medical Republic1 May 2024
Ozempic compounded in disgusting conditions
Medical Republic1 May 2024
Consultation to remove GLP-1 receptor agonist analogues from compounding exemption
TGA1 May 2024
Long-term weight loss effects of semaglutide in obesity without diabetes
Nature Medicine1 May 2024
Protecting Australians from unsafe compounding of replica weight loss products
Health.gov.au1 May 2024
Ozempic isn't approved for weight loss in Australia - so how do people keep getting it?
SBS News1 Apr 2024
FDA approves first treatment to reduce heart risk in adults with obesity
FDA.gov8 Mar 2024
TGA seizes compounded weight loss drugs from pharmacy
Medical Republic1 Feb 2024
About the Ozempic (semaglutide) shortage
TGA1 Jan 2024
Ozempic in Australia: everything you need to know
Healthy Male1 Jan 2024

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.